Angiogenesis: now and then

被引:45
作者
Costa, C
Soares, R
Schmitt, F
机构
[1] Univ Porto, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal
[2] Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY USA
[3] Univ Porto, Fac Med, P-4200465 Oporto, Portugal
关键词
angiogenesis; endothelial progenitor cells; VEGF receptors;
D O I
10.1111/j.1600-0463.2004.apm11207-0802.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Angiogenesis or new blood vessel formation plays an essential role during embryogenesis, adult vascular remodeling and in several pathological disorders, as in tumor development. Although sprouting of blood vessels is the principal angiogenic mechanism, additional ones, such as the recruitment of bone marrow-derived cells, have recently been described. These processes are controlled by several molecules, although members of the VEGF family of angiogenic factors and its receptors seem to be the main mediators. Initially, VEGF receptors were described as endothelial specific; however, further studies have reported their presence in several types of cells of non-endothelial origin, such as tumor cells. This VEGF receptor altered expression has suggested an angiogenesis-independent growth advantage mechanism on certain types of cancers by the generation of autocrine loops. A possible role in tumorigenesis and a potential novel target in cancer therapy have been hypothesized. Detection of other receptors and molecules considered to be angiogenic players has also been observed on tumor cells. Currently, their clinical significance as well as their potential as therapeutic targets for the treatment of certain cancers is being evaluated, having in mind the future development of promising mechanism-based therapies. The aspects mentioned above are the main focus of this review, which aims to throw light on recent findings respecting angiogenesis and novel therapeutic approaches.
引用
收藏
页码:402 / 412
页数:11
相关论文
共 89 条
  • [1] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
    Achen, MG
    Jeltsch, M
    Kukk, E
    Mäkinen, T
    Vitali, A
    Wilks, AF
    Alitalo, K
    Stacker, SA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) : 548 - 553
  • [2] Asada N, 2003, IN VITRO CELL DEV-AN, V39, P321
  • [3] Isolation of putative progenitor endothelial cells for angiogenesis
    Asahara, T
    Murohara, T
    Sullivan, A
    Silver, M
    vanderZee, R
    Li, T
    Witzenbichler, B
    Schatteman, G
    Isner, JM
    [J]. SCIENCE, 1997, 275 (5302) : 964 - 967
  • [4] Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
    Asahara, T
    Masuda, H
    Takahashi, T
    Kalka, C
    Pastore, C
    Silver, M
    Kearne, M
    Magner, M
    Isner, JM
    [J]. CIRCULATION RESEARCH, 1999, 85 (03) : 221 - 228
  • [5] VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
    Asahara, T
    Takahashi, T
    Masuda, H
    Kalka, C
    Chen, DH
    Iwaguro, H
    Inai, Y
    Silver, M
    Isner, JM
    [J]. EMBO JOURNAL, 1999, 18 (14) : 3964 - 3972
  • [6] Bachelder RE, 2001, CANCER RES, V61, P5736
  • [7] Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
    Barleon, B
    Sozzani, S
    Zhou, D
    Weich, HA
    Mantovani, A
    Marme, D
    [J]. BLOOD, 1996, 87 (08) : 3336 - 3343
  • [8] DIFFERENTIAL EXPRESSION OF THE 2 VEGF RECEPTORS FLT AND KDR IN PLACENTA AND VASCULAR ENDOTHELIAL-CELLS
    BARLEON, B
    HAUSER, S
    SCHOLLMANN, C
    WEINDEL, K
    MARME, D
    YAYON, A
    WEICH, HA
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 54 (01) : 56 - 66
  • [9] ZD1839 ('Iressa')1,2 as an anticancer agent
    Baselga, J
    Averbuch, SD
    [J]. DRUGS, 2000, 60 (Suppl 1) : 33 - 40
  • [10] Belgore FM, 2000, CIRCULATION, V102, pE108